证券记录 · 已归档季度
UTHR
United Therapeutics Corporation · Healthcare · Biotechnology
14被追踪持有人
n/aΔ持有人
8.17M持有股份
$2.60B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 86.02K | $43.82M | n/a | n/a |
| Q2 2026 | 157 | +4 | 27.98M | $15.17B | +8 | −5 |
| Q1 2026 | 157 | -1 | 29.64M | $17.54B | +5 | −7 |
| Q4 2025 | 157 | +1 | 32.29M | $15.72B | +2 | n/a |
| Q3 2025 | 21 | 0 | 20.11M | $8.43B | +1 | −2 |
| Q2 2025 | 19 | 0 | 20.17M | $5.79B | n/a | n/a |
| Q1 2025 | 16 | +1 | 10.14M | $3.12B | +1 | n/a |
| Q4 2024 | 15 | 0 | 10.52M | $3.71B | +1 | −1 |
| Q3 2024 | 14 | 0 | 8.99M | $3.22B | n/a | n/a |
| Q2 2024 | 14 | n/a | 8.17M | $2.60B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 3.29M | n/a | $1.05B | 0.2% | n/c | 1 | SEC ↗ ×9 |
| 2 | Renaissance Technologies ✦ | 2.17M | n/a | $692.75M | 1.2% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 1.05M | n/a | $333.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | AQR Capital Management ✦ | 719.51K | n/a | $229.20M | 0.4% | n/c | 1 | SEC ↗ ×3 |
| 5 | Arrowstreet Capital ✦ | 438.68K | n/a | $139.74M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 234.92K | n/a | $74.83M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 103.03K | n/a | $32.82M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Gotham Asset Management ✦ | 47.59K | n/a | $15.16M | 0.2% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 42.02K | n/a | $13.39M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Norges Bank ✦ (被动) | 38.93K | n/a | $12.40M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 20.11K | n/a | $6.40M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Bridgewater Associates ✦ | 12.75K | n/a | $4.06M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 5.16K | n/a | $1.64M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 1.90K | n/a | $605,245 | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 844 持有人, 41.22M 股份, $23.10B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 200 股 · $110,143
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 2.17K 股 · $1.19M
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 281 股 · $151,874
Oct 15
MAHON PAUL A
Officer · 268 股 · $145,160
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 456 股 · $247,462
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 601 股 · $328,713
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 371 股 · $201,599
Oct 15
MAHON PAUL A
Officer · 1.98K 股 · $1.08M
Oct 15
MAHON PAUL A
Officer · 791 股 · $430,975
Oct 15
ROTHBLATT MARTINE A
Officer, Director · 825 股 · $450,347
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A: ROTHBLATT MARTINE A
Aug 13
SC 13G/A: WELLINGTON MANAGEMENT GROUP LLP
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据